Amicus Therapeutics CFO Simon Harford cashes out $2.08M in equity as BioMarin acquisition closes

TL;DR: Amicus Therapeutics CFO Simon Harford disposed of 143,595 shares and vested RSUs for roughly $2.08 million as the BioMarin acquisition closed. All of his outstanding stock options were cancelled and paid out in cash at the $14.50 merger price.

Context Amicus Therapeutics (ticker: FOLD) completed its acquisition by BioMarin Pharmaceutical Inc. (ticker: BMRN) on October 2, 2023. Before the close, Amicus held a market capitalization of about $2.4 billion, while BioMarin’s stood near $16.5 billion. On the day the merger closed, Amicus shares rose 3.2% and BioMarin gained 0.8%, reflecting investor approval of the deal.

Key Facts Harford sold 108,478 common shares and 35,117 restricted stock units that vested fully upon the merger, each at $14.50, for a total of approximately $2.08 million. In addition, three stock‑option awards covering 189,043, 99,073 and 150,517 shares were cancelled. The merger terms exchanged each option for a cash payment equal to the difference between the $14.50 merger price and its exercise price, multiplied by the number of underlying shares. After these transactions, Harford holds no remaining common shares or options in Amicus.

What It Means The cash‑out converts Harford’s equity into liquidity, a standard outcome when executives’ awards are settled in a merger. With no lingering equity stake, his financial interest in the combined entity now derives solely from any cash proceeds or future salary. The transaction does not signal a change in the company’s strategic direction; it reflects the mechanical unwinding of compensation tied to the deal.

What to watch next Investors will monitor how BioMarin integrates Amicus’s pipeline, particularly its galactosidase‑deficiency therapies, and whether the combined firm updates its revenue guidance in the coming quarters.